Coordinated by EMA, the European Network of Centers for Pharmacoepidemiology & Pharmacovigilance (ENCePP) is an initiative that brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe with the aim to facilitate the conduct of high quality, multi-center, independent PASS with a focus on observational research. Becoming an ENCePP partner is an important step for QUANTIFY as we share the ideals of transparency, independence and high standard of research.
QUANTIFY is a provider of RWE including comparative effectiveness, safety, treatment patterns, epidemiology, burden of disease, and market access with extensive experience in a wide range of therapeutic/disease areas including gastrointestinal tract, immunosuppression, infectious diseases, liver disease, malignant disease, osteoporosis, pediatrics, pregnancy, psychiatry, renal impairment, respiratory diseases, and skin disorders. In-house, QUANTIFY hosts research programmes in Parkinson, Myeloma, CVD, Dermatology, Respiratory, Osteoporosis, Hepatology, and Spinal Disease, among others.
Read about QUANTIFY in the ENCePP resources database here.
Read more about ENCePP here.